Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122


Risk factors of treatment-limiting anemia after substitution of zidovudine for stavudine in HIV-infected adult patients on antiretroviral treatment.

Phe T, Thai S, Veng C, Sok S, Lynen L, van Griensven J.

PLoS One. 2013;8(3):e60206. doi: 10.1371/journal.pone.0060206. Epub 2013 Mar 26.


An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.

Li T, Guo F, Li Y, Zhang C, Han Y, Lye W, He Y, Lu H, Xie J, Huang A, Li Y, Tang X, Wang H, Zhang T, Gao G, Lei J, Zhang X, Wu X, Sun Y, Bai J, Luo L, Wang H.

Chin Med J (Engl). 2014;127(1):59-65.


Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).

Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P; Novavir Study Group.

Antimicrob Agents Chemother. 2002 Jun;46(6):1906-13.


Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting.

Kumarasamy N, Venkatesh KK, Devaleenol B, Saghayam S, Manohar D, Poongulali S, Yepthomi T, Ambrose P, Solomon S, Mayer KH.

Int J Infect Dis. 2009 Nov;13(6):e360-4. doi: 10.1016/j.ijid.2008.11.030. Epub 2009 Mar 27.


A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team.

Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, McKinney RE Jr, Nichols S, Mitchell WG, Yogev R, Hutcheon N.

Pediatrics. 1998 Feb;101(2):214-20.


Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.

Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ, Hoffmann CJ.

PLoS One. 2013 May 14;8(5):e64459. doi: 10.1371/journal.pone.0064459. Print 2013.


Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study.

Phan V, Thai S, Choun K, Lynen L, van Griensven J.

PLoS One. 2012;7(1):e30647. doi: 10.1371/journal.pone.0030647. Epub 2012 Jan 27.


Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals.

Spaulding A, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD008651. doi: 10.1002/14651858.CD008651. Review.


Evaluating the utility of early laboratory monitoring of antiretroviral-induced haematological and hepatic toxicity in HIV-infected persons in Cameroon.

Bekolo CE, Sonkoue C, Djidjou H, Bekoule PS, Kollo B.

BMC Infect Dis. 2014 Sep 25;14:519. doi: 10.1186/1471-2334-14-519.


Evaluation of incidence of zidovudine induced anemia in Indian human immunodeficiency virus positive patients in comparison with stavudine based highly active antiretroviral therapy.

Rajesh R, Vidyasagar S, Varma DM, Mohiuddin S, Noorunnisa.

Int J Risk Saf Med. 2011;23(3):171-80. doi: 10.3233/JRS-2011-0531.


Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing.

Willig JH, Echevarria J, Westfall AO, Iglesias D, Henostroza G, Seas C, Mugavero MJ, Allison J, Paz J, Hernandez F, Tomatis C, Saag MS, Gotuzzo E.

J Acquir Immune Defic Syndr. 2010 Feb;53(2):215-21. doi: 10.1097/QAI.0b013e3181bc0f10.


Evaluation of a systematic substitution of zidovudine for stavudine-based HAART in a program setting in rural Cambodia.

Isaakidis P, Raguenaud ME, Phe T, Khim SA, Kuoch S, Khem S, Reid T, Arnould L.

J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):48-54. doi: 10.1097/QAI.0b013e31817bec19.


Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.

Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe J Jr, Stool E, Jemsek JG, Dellamonica P, Cross A, Dunkle L.

Ann Intern Med. 1997 Mar 1;126(5):355-63.


Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.

Castelnuovo B, Kiragga A, Kamya MR, Manabe Y.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):59-63. doi: 10.1097/QAI.0b013e3181f5bd03.


A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1591-600.


A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).

Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1601-10.


Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine.

Lonergan JT, McComsey GA, Fisher RL, Shalit P, File TM Jr, Ward DJ, Williams VC, Hessenthaler SM, Lindsey L, Hernandez JE; ESS40010 (TARHEEL) Study Team.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):935-42.


Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire.

Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, Gomis OB, Konga C, Inwoley A, Gabillard D, Bissagnene E, Salamon R, Anglaret X.

Antivir Ther. 2005;10(5):615-24.


Supplemental Content

Support Center